Loading...
Jardiance
Antidiabetic • SGLT2 inhibitor
Inhibits sodium-glucose co-transporter 2 in proximal tubule, increasing urinary glucose excretion
Drug Class
Antidiabetic
Subclass
SGLT2 inhibitor
Half-life
12.4 hours
Time for plasma concentration to decrease by 50%
Protein Binding
86%
Fraction bound to plasma proteins
Therapeutic Index
Wide
Margin between therapeutic and toxic doses